The role of monocarboxylate transporter 8 during human placental development in normal and IUGR pregnancies
Lead Research Organisation:
University of Birmingham
Department Name: Clinical and Experimental Medicine
Abstract
There is a link between mild underactive thyroid gland activity in pregnant women and delayed mental development in offspring. Further investigation suggests that
maternal thyroid hormone (TH) has a direct effect on the baby’s brain development. This would rely on a well-functioning placenta to transport TH from the mother to the baby. Placental development itself is also influenced by TH, including a critical stage when the blood vessels within the wall of the womb are invaded by placental cells in order to form an effective placenta for exchange of essential factors between the mother and baby. In abnormal pregnancies where babies are not growing well (IUGR), impaired growth often stems from disruptions in placental development. Indeed, disorders of the thyroid gland in women are associated with an increased risk of placental disorders such as IUGR as
well as miscarriages, stillbirths and placental bleeding. Currently, our understanding of how the placenta transports TH and how the development of the placenta is affected by TH is very poor. Although the level of TH in the mother’s blood is a crucial factor, there are other factors which can modulate the effects of TH. One of these factors includes a protein found on cell surfaces called MCT8, which is a potent transporter of TH into cells. We aim to clarify the role of MCT8 within the placenta by studying its presence in human placenta and investigating differences between normal and IUGR pregnancies. We also propose to assess how MCT8 affects the properties of placental cells. Worldwide, disruptions in thyroid gland activity during pregnancy and IUGR are common findings, thus this proposed research would have widespread implications.
maternal thyroid hormone (TH) has a direct effect on the baby’s brain development. This would rely on a well-functioning placenta to transport TH from the mother to the baby. Placental development itself is also influenced by TH, including a critical stage when the blood vessels within the wall of the womb are invaded by placental cells in order to form an effective placenta for exchange of essential factors between the mother and baby. In abnormal pregnancies where babies are not growing well (IUGR), impaired growth often stems from disruptions in placental development. Indeed, disorders of the thyroid gland in women are associated with an increased risk of placental disorders such as IUGR as
well as miscarriages, stillbirths and placental bleeding. Currently, our understanding of how the placenta transports TH and how the development of the placenta is affected by TH is very poor. Although the level of TH in the mother’s blood is a crucial factor, there are other factors which can modulate the effects of TH. One of these factors includes a protein found on cell surfaces called MCT8, which is a potent transporter of TH into cells. We aim to clarify the role of MCT8 within the placenta by studying its presence in human placenta and investigating differences between normal and IUGR pregnancies. We also propose to assess how MCT8 affects the properties of placental cells. Worldwide, disruptions in thyroid gland activity during pregnancy and IUGR are common findings, thus this proposed research would have widespread implications.
Technical Summary
Studies investigating the link between maternal thyroid status and neurodevelopmental delay in offspring suggest a direct effect of maternal thyroid hormone (TH) on fetal brain development, which would rely on a well-functioning placenta for transplacental supply of TH. Placental development, including the trophoblastic invasion of the uterine spiral arteries to transform them into high-flow low-resistance vessels for effective maternal-fetal exchange, is itself TH-responsive as evidenced by in-vitro trophoblast studies. However, the molecular mechanisms mediating these processes remain poorly understood. Whilst circulating maternal THs are the major determinants of transplacental fetal TH supply and placental cell supply of the active ligand, triiodothyronine (T3), other factors modulate them including the plasma membrane transport of TH, the expression of iodothyronine deiodinase enzymes and thyroid hormone receptors (TRs). Intrauterine growth restriction (IUGR) contributes significantly to perinatal and neonatal mortality and morbidity. IUGR is associated with fetal hypothyroxinaemia and is accompanied by malplacentation with at least 50% of spiral arteries remaining ?untransformed?.
Hypothesis:
1) Monocarboxylate transporter 8 (MCT8), the most powerful TH plasma membrane transporter, plays an important role in both the transplacental transport of TH and TH-dependent placental development.
2) In the pathological state of IUGR, increased MCT8 and TR expression occurs as a compensatory mechanism attempting to facilitate TH action in trophoblasts.
Key experimental aims:
1) to define the gestational ontogeny and cellular localisation of MCT8, as well as its co-localisation with deiodinases and TRs in human villous placenta and placental bed from the first, second and third trimesters of pregnancy. We will compare differences between IUGR and normal placenta in the third trimester.
2) to investigate whether MCT8 transports factors in addition to TH (as suggested by observations of MCT8 in neurodevelopment).
3) to assess the effects of the level of MCT8 expression on the proliferation, survival and uterine invasion properties of primary cytotrophoblasts and extravillous trophoblasts.
4) to compare TH transport and functional characteristics [as in (3)] of primary cytotrophoblast from IUGR placenta with those from normal placenta.
5) to use gene arrays to identify thyroid hormone responsive genes and their downstream gene transcription effects in primary cytotrophoblasts, as well as assessing the broader T3-independent response modulated by MCT8 effects.
Conclusion:
These experiments will clarify the role of MCT8 in villous and extravillous trophoblasts, and how alterations in the level of MCT expression can affect placental development.
Hypothesis:
1) Monocarboxylate transporter 8 (MCT8), the most powerful TH plasma membrane transporter, plays an important role in both the transplacental transport of TH and TH-dependent placental development.
2) In the pathological state of IUGR, increased MCT8 and TR expression occurs as a compensatory mechanism attempting to facilitate TH action in trophoblasts.
Key experimental aims:
1) to define the gestational ontogeny and cellular localisation of MCT8, as well as its co-localisation with deiodinases and TRs in human villous placenta and placental bed from the first, second and third trimesters of pregnancy. We will compare differences between IUGR and normal placenta in the third trimester.
2) to investigate whether MCT8 transports factors in addition to TH (as suggested by observations of MCT8 in neurodevelopment).
3) to assess the effects of the level of MCT8 expression on the proliferation, survival and uterine invasion properties of primary cytotrophoblasts and extravillous trophoblasts.
4) to compare TH transport and functional characteristics [as in (3)] of primary cytotrophoblast from IUGR placenta with those from normal placenta.
5) to use gene arrays to identify thyroid hormone responsive genes and their downstream gene transcription effects in primary cytotrophoblasts, as well as assessing the broader T3-independent response modulated by MCT8 effects.
Conclusion:
These experiments will clarify the role of MCT8 in villous and extravillous trophoblasts, and how alterations in the level of MCT expression can affect placental development.
Organisations
- University of Birmingham, United Kingdom (Lead Research Organisation)
- University College London, United Kingdom (Collaboration)
- Institute of Zoology (Collaboration)
- St George's University of London, United Kingdom (Collaboration)
- Newcastle University, United Kingdom (Collaboration)
- Erasmus MC (Collaboration)
- Leibniz Association (Collaboration)
- University of Manchester, Manchester, United Kingdom (Collaboration)
- University of Dundee, United Kingdom (Collaboration)
Publications

Chan SY
(2014)
MCT8 expression in human fetal cerebral cortex is reduced in severe intrauterine growth restriction.
in The Journal of endocrinology

Chan SY
(2011)
The expression of thyroid hormone transporters in the human fetal cerebral cortex during early development and in N-Tera-2 neurodifferentiation.
in The Journal of physiology

James SR
(2009)
Monocarboxylate transporter 8 in neuronal cell growth.
in Endocrinology

Loubière LS
(2012)
Expression and function of thyroid hormone transporters in the microvillous plasma membrane of human term placental syncytiotrophoblast.
in Endocrinology


Pemberton HN
(2007)
Separase, securin and Rad21 in neural cell growth.
in Journal of cellular physiology

Smith VE
(2012)
PTTG-binding factor (PBF) is a novel regulator of the thyroid hormone transporter MCT8.
in Endocrinology

Vasilopoulou E
(2010)
Differential triiodothyronine responsiveness and transport by human cytotrophoblasts from normal and growth-restricted pregnancies.
in The Journal of clinical endocrinology and metabolism

Vasilopoulou E
(2013)
Monocarboxylate transporter 8 modulates the viability and invasive capacity of human placental cells and fetoplacental growth in mice.
in PloS one

Watkins RJ
(2010)
Pituitary tumor transforming gene binding factor: a new gene in breast cancer.
in Cancer research
Description | Research cited in reviews written for clinicians - brain |
Geographic Reach | North America |
Policy Influence Type | Citation in clinical reviews |
Impact | The clinical significance of research findings of thyroid hormone receptors and deiodinases in human fetal brain is discussed in two reviews targetting both practising Obstetricians and Endocrinologists. 1. Maternal thyroid hormones and fetal brain development. Current Opinion in Diabetes and Endocrinology (2005) 12(1):23-30. 2. Thyroid hormones in fetal central nervous system development. Fetal and Maternal Medicine Reviews (2003) 14: 177-208. 3. Thyroid hormones in pregnancy and the fetus. (2002) Chapter 6, pp 75-101; Progress in Obstetrics and Gynaecology (Volume 15) Churchill and Livingston, UK.; Increasing awareness of laboratory based findings amongsts clinicians and the impact on health care. This has indirectly led to the development of clinical guidelines for management of thyroid disease in pregnancy, details given in a separate outcome measure. |
Description | Research cited in reviews written for clinicians - placenta |
Geographic Reach | National |
Policy Influence Type | Influenced training of practitioners or researchers |
Impact | Our papers on deiodinases (PMID 12970328) and MCT8 (PMID 16731778) expression in the human placenta has been cited in several review articles including: 1. The role of the placenta in thyroid hormone delivery to the fetus. Nature Clinical Practice Endocrinology & Metabolism 2009. (PMID 19079273) 2. Placental transport of thyroid hormone. Best Pract Res Clin Endocrinol Metab. 2007;21(2):253-64 (PMID 17574007) ; Increasing awareness of laboratory based findings amongsts clinicians and the impact on health care. |
URL | http://europepmc.org/abstract/MED/12970328 |
Description | Action Medical Research project grant |
Amount | £182,012 (GBP) |
Funding ID | 1949 |
Organisation | Action Medical Research |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 04/2012 |
End | 01/2015 |
Description | Action Medical Research, Project Grant |
Amount | £105,970 (GBP) |
Organisation | Action Medical Research |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 11/2008 |
End | 11/2010 |
Description | BTF Project Grant |
Amount | £10,000 (GBP) |
Organisation | British Thyroid Foundation (BTF) |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 01/2010 |
End | 12/2010 |
Description | Birmingham Children's Hospital Research Foundation mall Project grant |
Amount | £70,000 (GBP) |
Organisation | BCH Charities |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 01/2012 |
End | 01/2012 |
Description | EME clinical trial |
Amount | £1,200,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 07/2011 |
End | 07/2015 |
Description | MRC DTA PhD studentship |
Amount | £50,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 10/2008 |
End | 11/2009 |
Description | Project Grant WoW |
Amount | £150,000 (GBP) |
Organisation | Wellbeing of Women |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 10/2009 |
End | 09/2012 |
Description | Springboard Fellowship Birmingham Women's Hospital R&D |
Amount | £45,000 (GBP) |
Organisation | BCH Charities |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 09/2011 |
End | 09/2012 |
Description | Travel Award |
Amount | £1,000 (GBP) |
Organisation | International Federation of Placenta Associations (IFPA) |
Sector | Academic/University |
Country | Global |
Start | 09/2008 |
End | 09/2008 |
Title | Amaxa nucleofection for trophoblasts |
Description | Amaxa nucleofection for primary cytotrophoblasts and choriocarcinoma cell lines: Cultures of primary cytotrophoblast had been notoriously difficult to transfect. We have successfully established the technique of Amaxa electroporation for gene transfection and silencing in our primary cytotrophoblast cultures. |
Type Of Material | Technology assay or reagent |
Provided To Others? | No |
Impact | We can now study for the first time the impact of over and under expression of a gene of interest in primary cytotrophoblast cultures in vitro. |
Title | Human fetal brain biopsies |
Description | We have a collection of fresh frozen biopsies of human fetal cerebral cortex from 6 weeks to 20 weeks gestation (about 70 samples) in our -80C freezer. All our samples are obtained from surgical terminations of pregnancies which eliminates the influence of termination-inducing drugs. The collection occurred between 1997 and 2001. |
Type Of Material | Database/Collection of Data/Biological Samples |
Provided To Others? | No |
Impact | We have a peer-reviewed publication arising from this brain collection: 1. Expression of thyroid receptor isoforms in the human fetal central nervous system and the effects of intrauterine growth restriction. Clin Endocrinol (Oxf). 2000 Oct;53(4):469-77 (PMID 11012572). 2. Early expression of thyroid hormone deiodinases and receptors in human fetal cerebral cortex. Developmental Brain Research 2002, 138: 109-16 (PMID 12354639). 3. A potential role for PTTG/securin in the developing human fetal brain. FASEB J. 2003; 17(12):1631-9 (PMID 12958169). 4. Separase, securin and Rad21 in neural cell growth. Journal of Cellular Physiology 2007, 213(1):45-53 (PMID 17450531). Other new data has been presented orally at international conferences (Expression of thyroid hormone transporters in human fetal brain. The Medical Research Society Meeting for Clinician Scientists, RCP, London, February 2008, and the 55th annual scientific meeting of the Society for Gynecologic Investigations, San Diego, March 2008. Reproductive Sciences Vol. 15 No. 2 Supp. p68A, 26) and manuscripts for publication are being written currently. A co-investigator presented a Visiting Professorial Lecture at the University of Hong Kong on "The role of thyroid hormones in fetal brain development" in December 2007. It has allowed us produce highly novel data describing the expressional ontogeny of several genes which has increased our understanding of the role played by thyroid hormones and different regulators of their actions during the course of development in the fetal brain. This has made an important contribution to the international debate and the recent clinical guidelines on screening for and optimising the treatment of maternal hypothyroidism from early pregnancy to reduce the risk of neurodevelopmental delay in the offspring. |
URL | http://europepmc.org/abstract/MED/11012572 |
Title | Human placental collection |
Description | We have a collection of fresh frozen biopsies of normal human villous placenta ranging from 6 weeks gestation to term (150 samples) as well as placenta from intrauterine growth restricted pregnancies and pregnancies complicated by pre-eclampsia (about 30 samples) in our -80C freezer. All our samples are obtained from either surgical terminations of pregnancies or non-labouring caesarean sections which eliminates the influence of termination-inducing drugs and hormonal changes during labour. The collection began in 1997 and is still on-going. It has involved a lot of researcher and clinician time in identifying suitable samples and collecting relevant clinical information. |
Type Of Material | Database/Collection of Data/Biological Samples |
Provided To Others? | No |
Impact | We have numerous peer-reviewed publications arising from this placental collection. It has allowed us to describe the expressional ontogeny of numerous genes and to assess the changes occuring in pathological pregnancies which has increased our understanding of the role played by different hormones in the placenta. Publications: 1. Circulating thyroid hormone concentrations and placental thyroid hormone receptor expression in normal human pregnancy and pregnancy complicated by intrauterine growth restriction (IUGR). J Clin Endocrinol Metab. 1998; 83(8):2964-71 (PMID 9709977). 2. Ontogeny of hepatocyte growth factor (HGF) and its receptor (c-met) in human placenta: reduced HGF expression in intrauterine growth restriction. Am J Pathol. 1998;153(4):1139-47 (PMID 9777945). 3. Reduced placental 11beta-hydroxysteroid dehydrogenase type 2 mRNA levels in human pregnancies complicated by intrauterine growth restriction: an analysis of possible mechanisms. J Clin Endocrinol Metab. 2001; 86(10):4979-83 (PMID 11600574). 4. Expression of 11 beta-hydroxysteroid dehydrogenase isozymes and corticosteroid hormone receptors in primary cultures of human trophoblast and placental bed biopsies. Mol Hum Reprod. 2001 Apr;7(4):357-63 (PMID 11279298). 5. The ontogeny of 25-hydroxyvitamin D(3) 1alpha-hydroxylase expression in human placenta and decidua. Am J Pathol. 2002;161(1):105-14 (PMID 12107095). 6. Placental iodothyronine deiodinase expression in normal and growth-restricted human pregnancies. J Clin Endocrinol Metab. 2003; 88(9):4488-95 (PMID 12970328) . 7. The use of laser capture microdissection (LCM) and quantitative polymerase chain reaction to define thyroid hormone receptor expression in human term placenta. Placenta. 2004; 25(8-9):758-62 (PMID 15450397). 8. Monocarboxylate transporter 8 expression in the human placenta: the effects of severe intrauterine growth restriction. Journal of Endocrinology 2006; 189(3): 465-71 (PMID 16731778). Abstracts: The Ontogenic Expression of Thyroid Hormone Transporters (MCT10, LAT1, LAT2, OATP4A1) In Human Placenta And Changes With Intrauterine Growth Restriction (IUGR). Oral presentation at The Blair Bell Research Society Meeting, Derby, June 2007 and the 78th American Thyroid Association Meeting, New York, 2007. Thyroid 17 Supp.1: S-106. Poster presentation at the International Federation of Placental Associations, Kingston, Ontario, 2007. Placenta 28: A.38, A5.12. paper submitted for publication. Co-investigator invited to give a Keynote Lecture at the Society of Endocinology meeting, Kensington. London in November 2006 on "The Placenta as a thyroid responsive organ". |
URL | http://europepmc.org/abstract/MED/9709977 |
Title | Production of MCT8 antibody |
Description | The MCT8 protein has been a very difficult protein to develop highly specific antibodies against. We have successfully produced our own specific MCT8 antibody which we have used successfully for a range of applications including Western immunoblottting, immunohistochemistry and FACS. |
Type Of Material | Antibody |
Provided To Others? | No |
Impact | Manuscript using this antibody is in preparation. |
Description | Erasmus Medical School |
Organisation | Erasmus MC |
Country | Netherlands |
Sector | Academic/University |
PI Contribution | access to data |
Collaborator Contribution | Intellectual contribution and shared expertise |
Impact | Co-author on publications PMID 16731778,12970328, 12844347, 12354639. Collaborator on Action medical Research Project Grant (2008-2010, £105k on MCT10 in placenta). |
Description | Jena, Germany |
Organisation | Leibniz Association |
Department | Leibniz Institute for Age Research |
Country | Germany |
Sector | Academic/University |
PI Contribution | Currently performing analysis on mouse placentae from knock-out mouse model |
Collaborator Contribution | Providing placenta from MCT8 knock out mouse model for further investigation |
Impact | Project grant from British Thyroid Foundation Jan-Dec 2010 |
Start Year | 2007 |
Description | Newcastle University |
Organisation | Newcastle University |
Department | Institute of Cellular Medicine |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | access to new data and authorship of publications. |
Collaborator Contribution | They have performed immunohistochemical studies in the placenta and trained staff from our group in new techniques. They are co-applicants on a grant awarded by the Wellbeing of Women on thyroid hormone effects in decidua. They are co-authors on recent Placenta publication. |
Impact | Co-authors on numerous publications (PMID: 16731778, 17911392, 16957024, 15598697, 15331405, 15219879 , 12970328, 12958169, 12107095, 20167367) Project grant from Wellbeing of Women, 2009-2012, £150k. |
Description | St. George's University of London |
Organisation | St George's University of London |
Department | Developmental and Endocrine Signalling Centre |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | access to data |
Collaborator Contribution | Training of staff in new techniques. Supply of an immortalised cell line. |
Impact | Co-authors on publication PMID:15598697. |
Description | UCL |
Organisation | University College London |
Department | Institute for Women's Health |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | To assess relationship between IUGR and thyroid status. |
Collaborator Contribution | To supply samples from a guinea pig model of IUGR. |
Impact | none yet. |
Start Year | 2012 |
Description | University Hospital Zurich |
Organisation | University of Zurich |
Country | Switzerland |
Sector | Academic/University |
PI Contribution | access to data |
Collaborator Contribution | provided antibodies for research |
Impact | Co-author on a recently published paper (20167367) and on another submitted paper. |
Start Year | 2007 |
Description | University of Dundee |
Organisation | University of Dundee |
Department | College of Life Sciences |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | access to data |
Collaborator Contribution | Provided antibodies for research. Co author on a paper. |
Impact | Co-author on a Placenta paper (20167367). |
Start Year | 2007 |
Description | University of Manchester |
Organisation | University of Manchester |
Department | School of Medicine Manchester |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | access to data |
Collaborator Contribution | Training of staff in new techniques |
Impact | Collaborator on a Action Medical Research Grant project grant |
Start Year | 2006 |
Description | University of Zurich |
Organisation | University of Zurich |
Country | Switzerland |
Sector | Academic/University |
PI Contribution | access to data |
Collaborator Contribution | Prof Verrey has provided us with antibodies for lab work. Shared expertise on MCT10. |
Impact | He is a collaborator on Action medical Research Project Grant (2008-2010, £105k on MCT10 in placenta). Co-author on a placenta paper (20167367). |
Start Year | 2007 |
Description | 2nd Endocrinology MA Healthcare Conference, London |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Primary Audience | Health professionals |
Results and Impact | A talk on "Hypothyroidism and subclinical thyroid dysfunction in pregnancy" was presented to about 50 Endocrinologists, Geriatricians, GPs and specialist trainees with useful discussions afterwards. Hopefully change of clinical practice in other parts of the country. |
Year(s) Of Engagement Activity | 2011 |
Description | 61st British Thyroid Association annual meeting |
Form Of Engagement Activity | Scientific meeting (conference/symposium etc.) |
Part Of Official Scheme? | No |
Type Of Presentation | Keynote/Invited Speaker |
Geographic Reach | National |
Primary Audience | Health professionals |
Results and Impact | 61st British Thyroid Association annual meeting, London, "The Physiology of Maternal and Foetal Thyroid Function", December 2012. Appreciative audience |
Year(s) Of Engagement Activity | 2012 |
Description | American Thyroid Association annual meetings |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Type Of Presentation | Paper Presentation |
Geographic Reach | International |
Primary Audience | Other academic audiences (collaborators, peers etc.) |
Results and Impact | Health Care professionals and basic science researchers from many countries participated. Presentation kindled lots of interest in subject. |
Year(s) Of Engagement Activity | 2007,2009 |
Description | Annual Refresher in Primary Maternity Care, Toronto |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Type Of Presentation | Keynote/Invited Speaker |
Geographic Reach | Regional |
Primary Audience | Health professionals |
Results and Impact | 10th Annual Refresher in Primary Maternity Care, Toronto, "Managing Thyroid Problems in Pregnancy", May 2012. Appreciative audience |
Year(s) Of Engagement Activity | 2012 |
Description | Blair Bell Research Society meetings |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Type Of Presentation | Paper Presentation |
Geographic Reach | National |
Primary Audience | Other academic audiences (collaborators, peers etc.) |
Results and Impact | Presented research on Vitamin D and pre-eclampsia Good discussion |
Year(s) Of Engagement Activity | 2007,2012 |
Description | British Endocrine Society annual meeting |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Primary Audience | Health professionals |
Results and Impact | A talk on "Hypothyroidism and Euthyroid TPO positivity in pregnancy" was given in a pregnancy symposium to a few hundred Endocrinologists, allied professionals and basic scientist. More invitations to speak at different meetings including lay audiences. |
Year(s) Of Engagement Activity | 2011 |
Description | British Endocrine Society meetings |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Type Of Presentation | Paper Presentation |
Geographic Reach | National |
Primary Audience | Health professionals |
Results and Impact | Basic science and clinical professionals from around Uk attended. Informed health care professionals of advances in basic science in their field. |
Year(s) Of Engagement Activity | 2009 |
Description | British Maternal and Fetal Medicine Society meetings |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Type Of Presentation | Paper Presentation |
Geographic Reach | National |
Primary Audience | Health professionals |
Results and Impact | Hundreds of Obstetricians from Uk and Ireland attended. In each of those meetings different oral presentations and poster presentations were presented by our research team. |
Year(s) Of Engagement Activity | 2009,2012,2013 |
Description | British Thyroid Foundation local meeting |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Primary Audience | Public/other audiences |
Results and Impact | About 15 Lay people, members of the local Birmingham BTF group attended to hear and discuss thyroid disorders in pregnancy. Invitations to other BTF groups across the UK. |
Year(s) Of Engagement Activity | 2011 |
Description | British Thyroid Foundation, Milton Keynes |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | Yes |
Type Of Presentation | Keynote/Invited Speaker |
Geographic Reach | Local |
Primary Audience | Participants in your research and patient groups |
Results and Impact | British Thyroid Foundation, Milton Keynes meeting, "How do hyperthyroidism and hypothyroidism affect pregnancy outcomes?", December 2011. Good discussion afterwards |
Year(s) Of Engagement Activity | 2012 |
Description | Graduate School Festival of Research and Enterprise, December 2007 |
Form Of Engagement Activity | Scientific meeting (conference/symposium etc.) |
Part Of Official Scheme? | No |
Type Of Presentation | Poster Presentation |
Geographic Reach | Local |
Primary Audience | Other academic audiences (collaborators, peers etc.) |
Results and Impact | graduate students from across the university attended Won 3rd prize in poster presemtation. |
Year(s) Of Engagement Activity | 2007 |
Description | International Federation of Placenta Associations Meetings |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Type Of Presentation | Poster Presentation |
Geographic Reach | International |
Primary Audience | Other academic audiences (collaborators, peers etc.) |
Results and Impact | Placentologists from around the world gathered for discussions. our team presented a fairly new aspect of placentaology to the field. |
Year(s) Of Engagement Activity | 2007,2008 |
Description | International Thyroid Congress |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Primary Audience | Health professionals |
Results and Impact | Several hundred clinicians and basic science researchers in the field of Thyroidalogy from all continents of the world met in Paris for the 14th ITC Meeting. A talk on "Thyroid hormone transport across the placenta" was given as part of a pregnancy symposia. The audience was more than expected for the auditorium and an additional auditorium with video relay had to be opened. There was much discussion afterwards. Closer discussion with other international research group working in the area. |
Year(s) Of Engagement Activity | 2010 |
Description | International symposium, Riga |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Primary Audience | Health professionals |
Results and Impact | Invited lecture to clinicians and scientists gven at the International symposium on Thyroid Hormone Action, Riga. None |
Year(s) Of Engagement Activity | 2008 |
Description | Iodine Status In The UK |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | Yes |
Type Of Presentation | Keynote/Invited Speaker |
Geographic Reach | International |
Primary Audience | Supporters |
Results and Impact | Iodine Status In The UK - The Way Forward: joint ICCIDD/BTF/BTA meeting, London, "Iodine, thyroid hormones and pregnancy", June 2012. Multidisciplinary involving policy makers, stake holders, industry, scientists and health professionals to discuss a national issue. |
Year(s) Of Engagement Activity | 2012 |
Description | Joint ICE/ECE meeting |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Type Of Presentation | Keynote/Invited Speaker |
Geographic Reach | International |
Primary Audience | Health professionals |
Results and Impact | Joint ICE/ECE meeting (International and European Congresses of Endocrinology), Florence, "Placental transport of thyroid hormone", May 2012. Appreciative audience |
Year(s) Of Engagement Activity | 2012 |
Description | Late breaking oral abstract 14th International thyroid Congress, 2010 |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Type Of Presentation | Paper Presentation |
Geographic Reach | International |
Primary Audience | Other academic audiences (collaborators, peers etc.) |
Results and Impact | Thousands of delegates from around the globe. Stimulated discussion of those in field. |
Year(s) Of Engagement Activity | 2010 |
Description | Mount Sinai Hospital, Toronto |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Type Of Presentation | Keynote/Invited Speaker |
Geographic Reach | Local |
Primary Audience | Health professionals |
Results and Impact | Mount Sinai Hospital, Toronto, "Subclinical thyroid dysfunction - should Obstetricians pay attention?" May 2012 discussions of controversial aspects of care. |
Year(s) Of Engagement Activity | 2012 |
Description | Nottingham |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Type Of Presentation | Keynote/Invited Speaker |
Geographic Reach | Local |
Primary Audience | Health professionals |
Results and Impact | Academic Division of Child Health, University of Nottingham, "Thyroid status and perinatal development", January 2012. Good discussion |
Year(s) Of Engagement Activity | 2012 |
Description | Perinatal Research Society |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Primary Audience | Health professionals |
Results and Impact | About 100 clinicians and basic scientists in the area of Obstetrics and Neonatology attended this meeting in West Virginia, USA. Further invitations to speak at other meetings in North America. |
Year(s) Of Engagement Activity | 2011 |
Description | Poster presentation BTA 2009 |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Type Of Presentation | Poster Presentation |
Geographic Reach | National |
Primary Audience | Health professionals |
Results and Impact | 100 attendees from UK from basic science and clinical backgrounds Won first prize for poster presentation. |
Year(s) Of Engagement Activity | 2009 |
Description | Presentation in Hong Kong |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Primary Audience | Health professionals |
Results and Impact | Invited to Hong Kong to give a series of lectures which have included our research work on MCT8 in placenta. None yet |
Year(s) Of Engagement Activity | 2009 |
Description | RCOG Annual Professional Development Conference |
Form Of Engagement Activity | Scientific meeting (conference/symposium etc.) |
Part Of Official Scheme? | No |
Type Of Presentation | Keynote/Invited Speaker |
Geographic Reach | National |
Primary Audience | Health professionals |
Results and Impact | Royal College of Obstetricians & Gynaecologists Annual Professional Development Conference, London, "Management of thyroid disease in pregnancy - can optimising therapy improve outcome", November 2012. Discussion on management of controversial areas. |
Year(s) Of Engagement Activity | 2012 |
Description | Traveller's meeting |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Primary Audience | Health professionals |
Results and Impact | A 15 minute oral presentation was made to both practising and retired consultant Obstetricians and Gynaecologists at a Traveller's meeting in Birmingham. The talk had highlighted for the first time the issues of thyroid hormone inadequecy in pregnancy upon placental and fetal development to some members of the audience. |
Year(s) Of Engagement Activity | 2007 |
Description | Trustess of Wellbeing of Women |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Primary Audience | Public/other audiences |
Results and Impact | Presented research to Trustees of Wellbeing of Women Charity. Further grant funding from Wellbeing of Women. |
Year(s) Of Engagement Activity | 2009 |
Description | Visit of research charity Action Medical Research to Birmingham |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Primary Audience | Public/other audiences |
Results and Impact | 2 members of staff from AMR Good feedback to contributors of funds to research charity |
Year(s) Of Engagement Activity | 2010 |